Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
160.2 USD | +0.39% | -4.79% | +3.15% |
05:26pm | BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating | MT |
02:52pm | Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.15% | 283B | |
+25.56% | 661B | |
+26.74% | 566B | |
-6.84% | 352B | |
+18.76% | 332B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.54% | 145B | |
-11.06% | 144B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie's Neutral Rating Maintained at Goldman Even as Skyrizi Sales Jump